公开(公告)号：US20220372122A1

公开(公告)日：2022-11-24

申请号：US17723149

申请日：2022-04-18

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol KIM ,  Jae Young SEONG ,  Jong Ik HWANG ,  Eun Bee CHO ,  Junho CHUNG ,  Junyeong JIN ,  Tae Young YUNE ,  Jee Youn LEE

IPC: C07K16/18 ,  G01N33/563 ,  C07K7/00

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20220144932A1

公开(公告)日：2022-05-12

申请号：US17290154

申请日：2019-12-31

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol KIM ,  Wonkyum KIM ,  Dong Sik KIM ,  Jae-Keun LEE ,  Jeongwon YOON ,  Junho CHUNG ,  Junyeong JIN

IPC: C07K16/24

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In some embodiments, antibodies are de-immunized to reduce immunogenicity in a human subject. In certain embodiments, antibodies have undergone affinity maturation. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g, inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20210347872A1

公开(公告)日：2021-11-11

申请号：US17285861

申请日：2019-10-15

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

IPC: C07K16/24 ,  A61P27/02

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a retinopathy (e.g., diabetic retinopathy) and/or maculopathy (e.g., age-related macular degeneration) in a subject in need thereof.

公开(公告)号：US20210070849A1

公开(公告)日：2021-03-11

申请号：US17050056

申请日：2019-04-24

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

IPC: C07K16/24 ,  A61P25/02

Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.

公开(公告)号：US20210054062A1

公开(公告)日：2021-02-25

申请号：US17054469

申请日：2019-05-10

Applicant: Neuracle Science Co., Ltd. ,  Seoul National University R&DB Foundation

Inventor： Bongcheol KIM ,  Wonkyum KIM ,  Jeongwon YOON ,  Junho CHUNG ,  Junyeong JIN ,  Eunhwoi YOU

IPC: C07K16/24 ,  A61K47/68 ,  A61K39/395 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00 ,  A61P29/00 ,  A61P25/02

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Ina specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20200223914A1

公开(公告)日：2020-07-16

申请号：US16626625

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd. ,  KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Bongcheol KIM ,  Eun Bee CHO ,  Dong Sik KIM ,  Jae-Keun LEE ,  Soon-gu KWON ,  Jae Young SEONG ,  Juwon SHIM ,  Tae Woo KIM ,  Shin-hyuk KANG

IPC: C07K16/24 ,  A61P35/00 ,  C07K16/30

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.